Published in Curr Cancer Drug Targets on March 01, 2010
Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer (2013) 2.44
NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 2.39
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol (2013) 1.38
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol (2011) 1.30
The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev (2014) 1.16
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology (2012) 1.14
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol (2014) 1.09
Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One (2012) 1.06
New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res (2012) 1.04
Immunotherapy targets in pediatric cancer. Front Oncol (2012) 0.97
Natural killer cells: role in local tumor growth and metastasis. Biologics (2012) 0.94
Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells. J Immunol (2013) 0.93
An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomedicine (2012) 0.88
Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model. J Transl Med (2012) 0.87
Therapeutic targets for neuroblastomas. Expert Opin Ther Targets (2014) 0.87
Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer (2014) 0.82
Antibody recognition of cancer-related gangliosides and their mimics investigated using in silico site mapping. PLoS One (2012) 0.81
Linker-free conjugation and specific cell targeting of antibody functionalized iron-oxide nanoparticles. J Mater Chem B Mater Biol Med (2014) 0.81
Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma. J Hematol Oncol (2016) 0.80
Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8. J Biol Chem (2015) 0.80
Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells. PLoS One (2014) 0.79
Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy. Mol Med (2013) 0.78
Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A. J AAPOS (2015) 0.78
Estradiol represses the G(D3) synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFκB binding to ST8SIA1 promoter. PLoS One (2013) 0.78
Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA. J Immunol Methods (2011) 0.78
Management of neuroblastoma: a study of first- and second-line chemotherapy responses, a single institution experience. Oncol Rev (2012) 0.75
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition. Oncotarget (2016) 0.75
Targeted immunotherapy for pediatric solid tumors. Oncoimmunology (2015) 0.75
Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. PLoS One (2015) 0.75
State of the art in anti-cancer mAbs. J Biomed Sci (2017) 0.75
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol (2017) 0.75
Nanomedicine as an innovative therapeutic strategy for pediatric cancer. Pediatr Surg Int (2015) 0.75
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol (1993) 10.87
Rat monoclonal antitubulin antibodies derived by using a new nonsecreting rat cell line. J Cell Biol (1982) 9.66
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem (2002) 4.11
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol (1987) 2.81
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol (2004) 2.16
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res (1984) 2.01
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res (1985) 1.78
Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood (2007) 1.77
Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res (2004) 1.76
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res (1987) 1.68
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol (1998) 1.67
High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods (1989) 1.65
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol (2001) 1.64
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol (2004) 1.64
Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood (1998) 1.64
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer (1997) 1.63
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer (1995) 1.59
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56
Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A (1992) 1.51
Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res (1989) 1.45
Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta (1994) 1.44
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol (1990) 1.44
A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother (1992) 1.44
Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol (1986) 1.42
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol (1998) 1.35
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol (2006) 1.32
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res (1997) 1.27
GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood (1989) 1.25
Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med (1996) 1.24
Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res (1987) 1.21
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol (1994) 1.17
Gangliosides of human melanoma. J Natl Cancer Inst (1987) 1.17
Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res (2005) 1.16
Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol (2007) 1.14
Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. Mol Immunol (2000) 1.14
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 1.12
Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res (1992) 1.12
Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A (1996) 1.11
Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res (1996) 1.10
Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res (1986) 1.10
Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res (1987) 1.08
Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol (1987) 1.06
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas (1992) 1.05
Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res (2002) 1.03
Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med (2004) 1.00
Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res (1987) 0.99
Monoclonal antibody mechanisms of action in cancer. Immunol Res (2007) 0.98
Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates. Blood (1990) 0.96
Novel antibodies as anticancer agents. Oncogene (2007) 0.95
Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother (1995) 0.95
Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst (2004) 0.92
Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother (1996) 0.91
GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer (1999) 0.87
Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. Cancer Immunol Immunother (2002) 0.87
Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res (2005) 0.86
Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res (2007) 0.85
In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int J Cancer (2003) 0.83
Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol Immunother (1995) 0.82
Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2. Int J Mol Med (2004) 0.81
Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies. Anticancer Res (1993) 0.80
Outcomes of hematopoietic stem cell transplant patients who received continuous renal replacement therapy in a pediatric oncology intensive care unit. Pediatr Crit Care Med (2010) 2.08
Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer (2007) 1.93
Selection of stem cells by using antibodies that target different CD34 epitopes yields different patterns of T-cell differentiation. Stem Cells (2006) 1.91
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol (2011) 1.79
Changes in outcomes (1996-2004) for pediatric oncology and hematopoietic stem cell transplant patients requiring invasive mechanical ventilation. Pediatr Crit Care Med (2008) 1.68
Pediatric cancers in the new millennium: dramatic progress, new challenges. Oncology (Williston Park) (2007) 1.60
Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer (2002) 1.60
Distinguishing benign from malignant pulmonary nodules with helical chest CT in children with malignant solid tumors. Radiology (2006) 1.42
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain (2010) 1.38
A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore) (2007) 1.37
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res (2004) 1.26
Establishment of ethical oversight of human research in El Salvador: lessons learned. Lancet Oncol (2006) 1.19
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol (2011) 1.18
Bone cancer. J Natl Compr Canc Netw (2013) 1.17
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. Cancer (2011) 1.11
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol (2014) 1.09
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res (2012) 1.06
Integration of palliative care practices into the ongoing care of children with cancer: individualized care planning and coordination. Pediatr Clin North Am (2008) 1.03
Working memory performance among childhood brain tumor survivors. J Int Neuropsychol Soc (2012) 1.02
Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer (2008) 0.99
Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res (2008) 0.98
Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91. J Clin Oncol (2009) 0.97
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol (2009) 0.94
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol (2006) 0.94
Population pharmacokinetic analysis of topotecan in pediatric cancer patients. Clin Cancer Res (2007) 0.93
Bone cancer. J Natl Compr Canc Netw (2010) 0.91
Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol (2015) 0.91
Significance of pleural effusion in neuroblastoma. Pediatr Blood Cancer (2007) 0.90
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol (2005) 0.90
Availability of palliative care services for children with cancer in economically diverse regions of the world. Eur J Cancer (2010) 0.89
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs (2011) 0.89
Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience. J Pediatr Surg (2010) 0.89
Percutaneous biopsy of pediatric solid tumors. Cancer (2005) 0.89
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol (2004) 0.88
Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol (2010) 0.88
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. Cancer Chemother Pharmacol (2005) 0.87
Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res (2005) 0.86
Impact of continuous renal replacement therapy on oxygenation in children with acute lung injury after allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer (2010) 0.86
Good clinical practice and the conduct of clinical studies in pediatric oncology. Pediatr Clin North Am (2008) 0.85
Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer (2009) 0.85
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr Blood Cancer (2011) 0.85
Immune therapies for neuroblastoma. Cancer Biol Ther (2009) 0.85
Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. J Immunother (2004) 0.84
Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant (2008) 0.83
Avoiding misdiagnosing neuroblastoma as Wilms tumor. J Pediatr Surg (2008) 0.82
Transfer of complex frontline anticancer therapy to a developing country: the St. Jude osteosarcoma experience in Chile. Pediatr Blood Cancer (2008) 0.81
Ethical considerations for pharmacogenomic testing in pediatric clinical care and research. Pharmacogenomics (2011) 0.81
64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. J Nucl Med (2012) 0.80
Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. Leuk Res (2004) 0.79
Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol (2004) 0.79
Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J Pediatr Hematol Oncol (2004) 0.78
A novel approach for the analysis of T-cell reconstitution by using a T-cell receptor beta-based oligonucleotide microarray in hematopoietic stem cell transplantation. Exp Hematol (2007) 0.78
Challenges faced by research ethics committees in El Salvador: results from a focus group study. Dev World Bioeth (2007) 0.77
Safety and diagnostic accuracy of tumor biopsies in children with cancer. Cancer (2014) 0.77
Clinical trials using irinotecan. J Pediatr Hematol Oncol (2002) 0.77
Agency and communication challenges in discussions of informed consent in pediatric cancer research. Qual Health Res (2010) 0.77
Radiographic assessment of resectability of locoregional disease in children with high-risk neuroblastoma during neoadjuvant chemotherapy. Pediatr Blood Cancer (2005) 0.76
The role of neoadjuvant chemotherapy in children with malignant solid tumors. Semin Pediatr Surg (2012) 0.76
Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR. J Pediatr Hematol Oncol (2006) 0.76
Adaptive functioning of childhood brain tumor survivors following conformal radiation therapy. J Neurooncol (2014) 0.76
Zygomycosis originating from an odontogenic infection in a pediatric oncology patient. Diagn Microbiol Infect Dis (2010) 0.75
Differential diagnosis and work-up of elevations of alkaline phosphatase following therapy for pediatric cancer. Pediatr Blood Cancer (2008) 0.75
Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. J Pediatr Hematol Oncol (2015) 0.75
Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood. Cancer (2008) 0.75
The nursing dimension of providing palliative care to children and adolescents with cancer. Clin Med Insights Pediatr (2012) 0.75
Tumor rupture and mitotic index in pediatric sex cord-stromal tumors. J Clin Oncol (2004) 0.75
Aggressive bladder carcinoma in a child. Pediatr Blood Cancer (2004) 0.75
Anemia and a large abdominal tumor in an adolescent. Pediatr Blood Cancer (2004) 0.75